Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

This study has been completed.
Information provided by:
Amgen Identifier:
First received: June 30, 2005
Last updated: December 2, 2010
Last verified: December 2010
The purpose of this study was to evaluate the effect of treatment with darbepoetin alfa on peak oxygen consumption (peak VO2) in subjects with symptomatic CHF and anemia.

Condition Intervention
Congestive Heart Failure
Drug: darbepoetin alfa

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Study to Assess the Impact of Subcutaneous (SC) Darbepoetin Alfa Treatment on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia

Resource links provided by NLM:

Further study details as provided by Amgen:

Primary Outcome Measures:
  • Exercise tolerance, measured as peak VO(subscript)2

Secondary Outcome Measures:
  • Exercise duration; *NYHA classification; *Patient-reported outcomes

Study Start Date: September 2002
Estimated Study Completion Date: July 2004

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Inclusion Criteria: - Symptomatic CHF for at least 3 months - Reduced left ventricular ejection fraction - Stable heart failure medication - Peak VO2 less than or equal to 16 ml/kg/min - Hemoglobin concentration between 9.0 and 12.0 g/dL Exclusion Criteria: - Hypertension - Unstable angina pectoris or recent myocardial infarction - Likely to receive cardiac transplant - Unable to do cardiopulmonary exercise testing - Major organ transplant (e.g., lung, liver, heart) or renal replacement therapy (e.g., dialysis) - Recent or current treatment for malignancy - Systemic hematologic disease - Anemia due to acute or chronic bleeding - Recent Epogen® or darbepoetin alfa therapy - Recent blood transfusion
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00117234

Sponsors and Collaborators
Study Director: MD Amgen
  More Information

Additional Information:
No publications provided by Amgen

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Global Development Leader, Amgen Inc. Identifier: NCT00117234     History of Changes
Other Study ID Numbers: 20020126
Study First Received: June 30, 2005
Last Updated: December 2, 2010
Health Authority: Ireland: Irish Medicines Board

Keywords provided by Amgen:
chronic heart failure
congestive heart failure
low hemoglobin
Symptomatic Congestive Heart Failure (CHF)

Additional relevant MeSH terms:
Heart Failure
Cardiovascular Diseases
Heart Diseases
Hematologic Diseases
Darbepoetin alfa
Hematologic Agents
Pharmacologic Actions
Therapeutic Uses processed this record on November 27, 2015